Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233375 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
A Phase 2 study of Metastatic Pancreatic Adenocarcinoma, sponsored by Clovis Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 13
- Study locations
NCT01233375: Completed Phase 2 study of Metastatic Pancreatic Adenocarcinoma, sponsored by Clovis Oncology.
NCT01233375 is a Phase 2 study of Metastatic Pancreatic Adenocarcinoma that has completed, run by Clovis Oncology. The registered enrollment target is 19 participants, below the 90-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (79% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233375, a Phase 2 study of Metastatic Pancreatic Adenocarcinoma, has completed, sponsored by Clovis Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
Conditions Studied
Interventions
- DRUG CO-1.01
Study Locations (13)
Florida
- Palm Beach Institute / Collaborative Research Group - Boynton Beach
- University of Miami - Miami
New York
- Memorial Sloan-Kettering Cancer Center - New York
- Columbia University Medical Center, Milstein Hospital - New York
Arizona
- Arizona Cancer Center at University of Arizona - Tucson
Colorado
- Rocky Mountain Cancer Center - Denver
Georgia
- Piedmont Healthcare Research Institute (PHRI) - Atlanta
Kentucky
- Norton Cancer Institute Research Program - Louisville
Maryland
- Johns Hopkins Oncology Center - Baltimore
Massachusetts
- Massachusetts General Hospital (MGH) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT01233375 record still lists
NCT01233375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 90-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which CO-1.01 is the first listed.
NCT01233375 lists 13 locations in 11 states (Florida, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT01233375 about?
NCT01233375 is a clinical study titled "Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma". The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
What is the current status of trial NCT01233375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2011-04. Estimated completion is 2013-03.
What conditions does trial NCT01233375 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT01233375?
The interventions under investigation include: CO-1.01 (DRUG).
Who is sponsoring clinical trial NCT01233375?
This trial is sponsored by Clovis Oncology, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01233375 being conducted?
This trial has 13 study locations across Arizona, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01233375's enrollment target sits among peer trials
19 30th of 37 higher than 7 of 37 other Metastatic Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia